SCYNEXIS, Inc. (SCYX) Dividend History

Company News

• Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsight

  A leading company engaged DelveInsight to conduct a comprehensive study on the myopia market, including prevalence, treatment patterns, and market forecasts across the APAC region. DelveInsight's analysis provided strategic insights to help the client optimize its market entry and differentiation strategies.

  GlobeNewswire Inc.

  Featured Companies: EYEN
• SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

  SCYNEXIS, a biotechnology company, announced upcoming presentations of preclinical data on its second-generation antifungal compound SCY-247 at IDWeek 2024. SCY-247 is in pre-IND development and has shown broad-spectrum antifungal activity, including against multidrug-resistant pathogens.

  GlobeNewswire Inc.
• SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

  JERSEY CITY, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended March 31, 2024.

  GlobeNewswire Inc.
• SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

  JERSEY CITY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 at the ESCMID Global 2024 congress (formerly known as ECCMID) in Barcelona, Spain from April 27-30, 2024.

  GlobeNewswire Inc.
• SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

  JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024.

  GlobeNewswire Inc.